View Author
dai: 298681404
scopus: 7006403331
Zwarthoff, E.C.
(Ellen Zwarthoff)Supervisor (promotor) of 3 dissertations
cancer patient mutation bladder tumor recurrence urine bladder cancer study analysis fgfr 3 mutations expression detection marker sample cystoscopy grade surveillance factor carcinoma fgfr 3 protein result tumours tumour stage urothelial sensitivity wild-type progression urine samples fgfr 3 mutation growth table igfbp van der kwast receptor microsatellite follow-up assay prognostic survival breast status group disease urology number bladder tumors microsatellite analysis tissue ficial bladder cancer pattern model urothelial cell carcinoma fgfr 3 status value prognostic factors cytology figure zwarthoff erasmus mc fication mn 1–tel erasmu response pathway effect zwarthoff ec month speci ficity method university pathology test arm level 1–tel speci treatment specificity
10 Most Recent Publications
|
DNA methylation-based biomarkers in bladder cancer
(Article)
Kandimalla, R. Tilborg, A.A. van Zwarthoff, E.C. |
2013-04-30
|
|
FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies
(Article)
Kessel, K.E.M. van Kompier, L.C. Bekker-Grob, E.W. de Zuiverloon, T.C.M. Vergouwe, Y. Zwarthoff, E.C. Steyerberg, E.W. |
2013-03-22
|
|
Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: A systematic review
(Article)
Zuiverloon, T.C.M. Nieuweboer, A.J.M. Vékony, H. Kirkels, W.J. Bangma, C.H. Zwarthoff, E.C. |
2012-01-01
|
|
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)
(Article)
Daniels, M. Lurkin, I. Stengel, B. Prall, F. Hertel, K. Lobeck, H. Popp, B. Theissig, F. Wünsch, P. Zwarthoff, E.C. Agaimy, A. Schneider-Stock, R. Pauli, R. Erbstößer, E. Hildebrandt, U. Hellwig, K. Zschille, U. Lüders, P. Krüger, G. Knolle, J. |
2011-12-15
|
|
Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay
(Article)
Zuiverloon, T.C.M. Tjin, S.S. Busstra, M. Bangma, C.H. Boeve, E.R. Zwarthoff, E.C. |
2011-08-01
|
|
No evidence of FGFR3 mutations in prostate cancer
(Article)
Zuiverloon, T.C.M. Boormans, J.L. Trapman, J. Leenders, G.J. van Zwarthoff, E.C. |
2011-05-01
|
|
FGFR3, HRAS, KRAS, NRAS AND PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy
(Article)
Kompier, L.C. Lurkin, I. Aa, M.N.M. van der Rhijn, B.W.G. van Kwast, Th.H. van der Zwarthoff, E.C. |
2010-11-18
|
|
Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)
(Article)
Roobol, M.J. Bangma, C.H. el Bouazzaoui, S. Franken-Raab, C.G. Zwarthoff, E.C. |
2010-11-01
|
|
Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle - Invasive bladder cancer
(Article)
Zuiverloon, T.C.M. Aa, M.N.M. van der Kwast, Th.H. van der Steyerberg, E.W. Roozenbeek, B. Bangma, C.H. Zwarthoff, E.C. |
2010-06-01
|
|
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
(Article)
Hollestelle, A. Nagel, J.H.A. Riaz, M. Koopman, D.G. Hagen, T.L.M. ten Leeuw, B. de Zwarthoff, E.C. Teunisse, A. Spek, P.J. van der Klijn, J.G.M. Dinjens, W.N.M. Ethier, S.P. Smid, M. Clevers, H.C. Jochemsen, A.G. Bakker, M.A. den Foekens, J.A. Martens, J.W.M. Schutte, A.E.M. Lam, S. Elstrodt, F. Wasielewski, M. Ng, S.S. French, P.J. Peeters, J. Rozendaal, M.J. |
2010-05-01
|
